TY - JOUR
T1 - From fibrinolysis to the plasminogen-plasmin system and beyond
T2 - A remarkable growth of knowledge, with personal observations on the history of fibrinolysis
AU - Kwaan, Hau C.
PY - 2014/7
Y1 - 2014/7
N2 - Great advances have been made in our understanding of the fibrinolytic system from the initial discovery of proteolysis of fibrin by plasmin to the multifaceted and complex role of the plasminogen-plasmin (P-P) system. We now know that the P-P system is composed of several serine proteases and their inhibitors (serpins). This system is involved in many physiological functions, including embryogenesis, cell migration, and wound healing. They also play an important role in the pathogenesis of many diseases, including atherosclerosis, obesity, cancer, and even autoimmune disorders, and neuronal degeneration. Knowledge of their role in cancer enables their use as a prognostic factor. Therapeutic use of various forms of proteases derived from this system has been employed as thrombolytic agents. In addition, small molecules designed to inhibit many of the components of the P-P system are now available for clinical trial, aimed at treatment of these various disorders. The history of such remarkable development of our knowledge on fibrinolysis is reviewed in this article.
AB - Great advances have been made in our understanding of the fibrinolytic system from the initial discovery of proteolysis of fibrin by plasmin to the multifaceted and complex role of the plasminogen-plasmin (P-P) system. We now know that the P-P system is composed of several serine proteases and their inhibitors (serpins). This system is involved in many physiological functions, including embryogenesis, cell migration, and wound healing. They also play an important role in the pathogenesis of many diseases, including atherosclerosis, obesity, cancer, and even autoimmune disorders, and neuronal degeneration. Knowledge of their role in cancer enables their use as a prognostic factor. Therapeutic use of various forms of proteases derived from this system has been employed as thrombolytic agents. In addition, small molecules designed to inhibit many of the components of the P-P system are now available for clinical trial, aimed at treatment of these various disorders. The history of such remarkable development of our knowledge on fibrinolysis is reviewed in this article.
KW - PAI-1
KW - fibrinolysis
KW - plasminogen
KW - plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=84905251142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905251142&partnerID=8YFLogxK
U2 - 10.1055/s-0034-1383545
DO - 10.1055/s-0034-1383545
M3 - Article
C2 - 25000957
AN - SCOPUS:84905251142
SN - 0094-6176
VL - 40
SP - 585
EP - 591
JO - Seminars in thrombosis and hemostasis
JF - Seminars in thrombosis and hemostasis
IS - 5
ER -